Ark slumps after gene therapy Cerepro rejected in EU for brain cancer
This article was originally published in Scrip
Ark Therapeutics' Cerepro (sitimagene ceradenovec), which could have become the first gene therapy approved in the EU, has been rejected by the CHMP for the treatment of operable high grade glioma (brain cancer), leading to a 50% fall in the company’s share price on the London Stock Exchange on December 18th. The company plans to appeal the decision immediately and expects the appeal process to take about four months.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.